Valeant expects to reduce its combined workforce by 10 to 15 percent upon completion of the $8.7 billion Bausch + Lomb buyout, according to a Healio report.
The company, which employed 7,500 people before the consolidation, does not anticipate laying off workers in North America. Bausch + Lomb employs 11,000 people worldwide.
Once the reorganization is complete, Valeant will keep Bausch + Lomb's name, and the health business will be headquartered in New Jersey. Transaction details will be finalized in early August.
More Articles on Ophthalmology:
Jules Stein Eye Institute, Doheny Eye Institute Intend to Develop Long-Term Affiliation
Southgate Surgery Center in Michigan Acquires ORA System for Cataract Surgery
Vista Eye Specialists of Virginia Uses New Toric Lens Technology to Treat Astigmatism